Detalhe da pesquisa
1.
Appropriate management of cutaneous adverse events maximizes compliance with sorafenib treatment: a single-center experience.
Future Oncol
; 8(5): 609-15, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22646774